期刊
EXPERT OPINION ON DRUG DISCOVERY
卷 13, 期 10, 页码 919-931出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17460441.2018.1514386
关键词
Intrinsic resistome; multidrug efflux pumps; inhibitors of resistance; Gram-negative infections
资金
- Instituto de Salud Carlos III (Spanish Network for Research on Infectious Diseases) [RD16/0016/0011]
- Spanish Ministry of Economy and Competitiveness [BIO2017-83128-R]
- Autonomous Community of Madrid [B2017/BMD-3691]
Introduction: One of the possibilities for reducing the emergence and spread of antibiotic resistance is the use of anti-resistance compounds capable of resensitizing resistant microorganisms to current antimicrobials. For this purpose, multidrug efflux pumps, whose inhibition may increase bacterial susceptibility to several antibiotics, including macrolides to which Gram-negatives are considered intrinsically resistant, have emerged as suitable targets. Areas covered: In the current review, the authors discuss different mechanisms that can be exploited for inhibiting multidrug efflux pumps and describe the properties and the potential therapeutic value of already studied efflux pumps inhibitors. Although efforts have already been made to develop these inhibitors, there are currently no good candidates for treating infectious diseases. Consequently, the authors also discuss potential approaches for their development. Expert opinion: Classical anti-resistance drugs such as beta-lactamases inhibitors, while useful, are only purposeful for treating infections caused by beta-lactamase producers. However, inhibitors of multidrug efflux pumps, which are present on all organisms, can sensitize both susceptible and resistant bacteria to antibiotics belonging to several different structural families. Since some efflux pumps are involved in bacterial infections, their inhibition may also reduce the infectivity of Gram-negative bacterial pathogens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据